CALC

CalciMedica Presentations: CalciMedica Inc. will present a poster on acute pancreatitis at Digestive Disease Week 2025 and participate in oral presentations and panel discussions at the American Society of Nephrology conference in May 2025.

Company Focus: CalciMedica is a biopharmaceutical company developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with ongoing clinical trials for conditions such as acute pancreatitis and COVID pneumonia.

Company Presentation: CalciMedica Inc. will have its CEO, Dr. Rachel Leheny, present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, with a live webcast available on their IR website.

Research Focus: CalciMedica is developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with ongoing clinical trials for conditions such as acute pancreatitis, COVID pneumonia, and acute kidney injury.

Auxora's Efficacy in AKI: A post-hoc analysis from the Phase 2 CARDEA trial revealed that patients with acute kidney injury (AKI) treated with Auxora experienced a 62.7% relative reduction in mortality at day 30 compared to placebo, with this effect persisting through day 60.

Ongoing Clinical Trials: CalciMedica is conducting a Phase 2 trial of Auxora for patients with Stage 2 or Stage 3 AKI and acute hypoxemic respiratory failure, with results expected in 2025, while also highlighting the potential therapeutic benefits of CRAC channel inhibition in treating inflammatory and immunologic diseases.

CalciMedica Presentation Announcement: CalciMedica Inc. will present at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference in San Diego, focusing on the role of ORAI-1 in acute kidney injury, with Dr. Sudarshan Hebbar as the presenter.

Company Overview: CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with ongoing trials for conditions like acute pancreatitis, COVID pneumonia, and acute kidney injury.

Company Presentation Announcement: CalciMedica Inc. will have its CEO, Rachel Leheny, present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, with a live webcast available on their investor relations website.

Focus on CRAC Channel Inhibition: CalciMedica is developing therapies targeting calcium release-activated calcium (CRAC) channels for inflammatory and immunologic diseases, with ongoing clinical trials for conditions like acute pancreatitis, COVID pneumonia, and acute kidney disease.

Appointment Announcement: CalciMedica Inc. has appointed Dr. Alan Glicklich to its Board of Directors, effective January 15, 2025, bringing over 20 years of biotechnology experience to the company as it advances its clinical trials for Auxora in treating acute pancreatitis and acute kidney injury.

Company Overview: CalciMedica is focused on developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with promising results from multiple Phase 2 clinical trials for its lead product candidate, Auxora, which aims to address significant unmet medical needs.

Company Presentation Announcement: CalciMedica Inc. will have its CEO, Rachel Leheny, present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, with a live webcast available on their investor relations website.

Focus on CRAC Channel Inhibition: CalciMedica is developing therapies targeting calcium release-activated calcium (CRAC) channels for inflammatory and immunologic diseases, with ongoing clinical trials for conditions like acute pancreatitis, COVID pneumonia, and acute kidney disease.

Presentation Announcements: Prof. Robert Sutton will present findings from the Phase 2b CARPO trial of Auxora™ for Acute Pancreatitis at the American Pancreatic Association (APA) 2024 Annual Meeting and will also showcase a poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting, both taking place in Maui, HI.

Company Overview: CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing therapies targeting CRAC channels for inflammatory and immunologic diseases, with promising results from its lead product candidate, Auxora™, in various clinical trials.

Clinical Trial Updates: CalciMedica announced positive results from its Phase 2b CARPO trial of Auxora™ in acute pancreatitis, showing significant reductions in respiratory failure and plans to initiate a Phase 3 program in 2025. Ongoing trials for acute kidney injury and asparaginase-induced pancreatic toxicity are also expected to yield data in 2025.

Financial Position: Following a public offering, CalciMedica's cash reserves are projected to support operations into the first half of 2026, despite reporting a net loss of approximately $5.6 million for the third quarter of 2024.

Clinical Trial Updates: CalciMedica announced positive results from its Phase 2b CARPO trial of Auxora™ in acute pancreatitis, showing significant reductions in respiratory failure and plans to initiate a Phase 3 program in 2025. Ongoing trials for acute kidney injury and asparaginase-induced pancreatic toxicity are also expected to yield data in 2025.

Financial Position: Following a public offering, CalciMedica's cash reserves are projected to support operations into the first half of 2026, despite reporting a net loss of approximately $5.6 million for the third quarter of 2024.

Leadership Change at CalciMedica: CalciMedica, a biopharmaceutical company, has appointed Stephen Bardin as Chief Financial Officer, succeeding Daniel Geffken, who will depart after the third quarter financial statements are filed. Bardin brings extensive experience from his previous roles in various biotech firms.

Clinical Progress and Future Trials: Bardin highlighted the promising results from CalciMedica's recent clinical trials, particularly for acute pancreatitis and ongoing studies for acute kidney injury, indicating optimism for future developments in their therapeutic pipeline.

Carvana's Financial Performance: Carvana Co. shares surged 20.3% in pre-market trading after reporting third-quarter revenue of $3.66 billion and earnings of 64 cents per share, both exceeding analyst expectations.

Market Movements: Several stocks experienced significant pre-market gains, including Root, Inc. (+79.1%) and Remitly Global, Inc. (+20.7%), while others like Equillium, Inc. (-42%) and Office Properties Income Trust (-34%) saw notable declines following their quarterly results.

Public Offering Announcement: CalciMedica, Inc. has priced an underwritten public offering of 2,720,000 shares of common stock at $3.75 per share, aiming to raise approximately $10.2 million before expenses, with the offering expected to close on November 1, 2024.

Company Overview: CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies targeting calcium release-activated calcium (CRAC) channels for inflammatory and immunologic diseases, with ongoing clinical trials for its lead product candidate, Auxora™.

Public Offering Announcement: CalciMedica, Inc. has initiated an underwritten public offering of its common stock, with the potential for the underwriter to purchase an additional 15% of shares sold, subject to market conditions.

Company Overview and Trials: CalciMedica is focused on developing CRAC channel inhibition therapies for inflammatory diseases, with ongoing clinical trials for its lead product candidate Auxora™ showing promising results in various conditions including acute pancreatitis and COVID pneumonia.

Positive Results from CARPO Trial: The Phase 2b CARPO trial of Auxora™ demonstrated a significant reduction in severe respiratory failure and persistent respiratory failure among patients with acute pancreatitis, indicating its potential as an effective treatment option.

Future Developments: CalciMedica plans to discuss the design of a Phase 3 trial for Auxora with the FDA, following encouraging results that highlight its immunomodulatory effects and organ protection capabilities.

Conference Call Announcement: CalciMedica Inc. will host a conference call and webcast on October 30, 2024, at 12 p.m. ET to discuss the full data set from its Phase 2b CARPO trial of Auxora™ for acute pancreatitis with systemic inflammatory response syndrome.

Company Overview: CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies targeting CRAC channels for inflammatory and immunologic diseases, with promising results from multiple clinical trials including those for COVID pneumonia and acute kidney injury.

Conference Call Announcement: CalciMedica Inc. will host a conference call and webcast on October 30, 2024, at 12 p.m. ET to discuss the full data set from its Phase 2b CARPO trial of Auxora™ for acute pancreatitis with systemic inflammatory response syndrome.

Company Overview: CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies targeting CRAC channels for inflammatory and immunologic diseases, with promising results from multiple clinical trials including those for COVID pneumonia and acute kidney injury.

CalciMedica Presentation Announcement: CalciMedica Inc. announced that a late-breaking abstract by Prof. Robert Sutton will be presented at the ACG 2024 Annual Scientific Meeting, focusing on their clinical trial for acute pancreatitis with systemic inflammatory response syndrome.

Company Overview and Clinical Trials: CalciMedica is developing CRAC channel inhibition therapies for inflammatory diseases, with ongoing and planned clinical trials for conditions like acute pancreatitis, COVID pneumonia, and acute kidney injury, showcasing promising results from their lead product candidate, Auxora™.

Insider Transactions Overview: Recent insider purchases in penny stocks include CalciMedica's CEO buying 1,000 shares at $4.19, Zevia PBC's director acquiring 13,705 shares at $1.09, and Ault Alliance's executive chairman purchasing 3,800 shares at $0.23, reflecting varying levels of confidence amid recent financial performances.

Company Profiles: CalciMedica focuses on therapies for inflammatory diseases, Zevia PBC offers zero-calorie beverages, and Ault Alliance, soon to be renamed Hyperscale Data, operates a Bitcoin mining data center and supports various industries.

CalciMedica Q2 2024 Earnings Report: CalciMedica reported a second quarter earnings per share of -36 cents, surpassing analyst expectations of -52 cents, but did not generate any revenue for the quarter.

InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes automated data from TradeSmith to quickly publish key financial figures and comparisons with analyst estimates without human intervention.